Rethinking furosemide use for infants with bronchopulmonary dysplasia

Pediatr Pulmonol. 2020 May;55(5):1100-1103. doi: 10.1002/ppul.24722. Epub 2020 Mar 16.

Abstract

Diuretics are commonly administered to infants with bronchopulmonary dysplasia (BPD) to improve respiratory function despite the absence of prospective data demonstrating long term benefits. While many potentially adverse effects of furosemide are known to clinicians, its direct and indirect impact on multiple pathophysiological processes need to be understood. While furosemide likely has a role in the management of infants with BPD, clinicians are encouraged to recognize these potential complications associated with furosemide administration. Specifically, a deeper understanding of the impact of diuretics on sodium metabolism neurohumoral regulation of cardiopulmonary physiology is required.

Keywords: aldosterone; angiotensin; bronchopulmonary dysplasia; furosemide; neonate.

Publication types

  • Comment

MeSH terms

  • Bronchopulmonary Dysplasia*
  • Chronic Disease
  • Furosemide*
  • Hospitalization
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Intensive Care Units, Neonatal
  • Prospective Studies

Substances

  • Furosemide